Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial
Giora Weisz(Columbia University Irving Medical Center), Gregg W. Stone(Cardiovascular Institute of the South), Gilles Montalescot(Maastricht University Medical Centre), Amir Lerman(Mayo Clinic in Arizona), Ramin Farzaneh‐Far, Ori Ben‐Yehuda(University of San Diego), Harvey D. White(University of Auckland), Karen P. Alexander(Clinical Research Institute), Ann Olmsted(Carolina Veterinary Specialists), E. Magnus Ohman(Duke University), Gennyne Walker(aTyr Pharma (United States)), B. Debruyne, Ehtisham Mahmud(Cardiovascular Institute of the South)
Cited by 23
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k